Journal of Clinical Virology最新文献

{"title":"Sequence analysis of respiratory syncytial virus cases reveals a novel subgroup -B strain circulating in north-central Italy after pandemic restrictions","authors":"Alessandra Pierangeli ,&nbsp;Fabio Midulla ,&nbsp;Antonio Piralla ,&nbsp;Guglielmo Ferrari ,&nbsp;Raffaella Nenna ,&nbsp;Antonino Maria Guglielmo Pitrolo ,&nbsp;Amelia Licari ,&nbsp;Gian Luigi Marseglia ,&nbsp;Dario Abruzzese ,&nbsp;Laura Pellegrinelli ,&nbsp;Cristina Galli ,&nbsp;Sandro Binda ,&nbsp;Danilo Cereda ,&nbsp;Matteo Fracella ,&nbsp;Giuseppe Oliveto ,&nbsp;Roberta Campagna ,&nbsp;Laura Petrarca ,&nbsp;Elena Pariani ,&nbsp;Guido Antonelli ,&nbsp;Fausto Baldanti","doi":"10.1016/j.jcv.2024.105681","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105681","url":null,"abstract":"<div><h3>Background</h3><p>Following the pandemic restrictions, the epidemiology of respiratory syncytial virus (RSV) has changed, leading to intense hospitalization peaks.</p></div><div><h3>Objectives</h3><p>This study, conducted at multiple sites in Italy, aimed to describe the temporal dynamics of two post-COVID-19 RSV epidemics. Additionally, the circulating RSV-A and -B lineages were characterized and compared to those found in 2018 and 2019.</p></div><div><h3>Study design</h3><p>Respiratory specimens and data were collected from RSV-positive patients, both inpatients, and outpatients, of all ages at three sites in north-central Italy. To analyze these samples, roughly one-sixth were sequenced in the attachment glycoprotein G gene and subjected to phylogenetic and mutational analyses, including pre-pandemic sequences from north-central Italy.</p></div><div><h3>Results</h3><p>The first post-pandemic surge of RSV cases was quite intense, occurring from October 2021 to early January 2022. The subsequent RSV epidemic (from November 2022 to early March 2023) also had a high impact, characterized by a rise in elderly patient cases. Post-pandemic cases of RSV-A were caused by various strains present in Italy prior to COVID-19. In contrast, a distinct RSV-B lineage, which was concurrently spreading in other countries, was identified as the main cause of the surge in 2022–2023 but remained undetected in Italy before the pandemic.</p></div><div><h3>Conclusions</h3><p>This study describes the temporal dynamics of post-pandemic RSV subgroups and uncovers a lineage of RSV-B with high genetic divergence that may have increased the impact of decreased population immunity.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"173 ","pages":"Article 105681"},"PeriodicalIF":8.8,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S138665322400043X/pdfft?md5=87c6b5e5ee92124e35ee607621411bbb&pid=1-s2.0-S138665322400043X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140906155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a fully automated high-throughput serology assay for detection of Hepatitis D virus antibodies","authors":"Xiaoxing Qiu ,&nbsp;Abbas Hadji ,&nbsp;Ana Olivo ,&nbsp;Austin Hodges ,&nbsp;Carla Beertsen ,&nbsp;Mark Anderson ,&nbsp;Mary Rodgers ,&nbsp;Dora Mbanya ,&nbsp;Susan Elaborot ,&nbsp;Gavin Cloherty","doi":"10.1016/j.jcv.2024.105689","DOIUrl":"10.1016/j.jcv.2024.105689","url":null,"abstract":"<div><h3>Background</h3><p>HDV antibody testing is recommended for universal screening and as the first line in an HDV double reflex testing strategy for effectively identifying patients with active infection for therapeutic treatments.</p></div><div><h3>Objective</h3><p>The aim of this study is to evaluate the performance of a newly developed ARCHITECT HDV Total Ig (ARCHITECT HDV Ig) prototype assay.</p></div><div><h3>Study design</h3><p>Performance characteristics were determined for the ARCHITECT HDV Ig and a reference test, LIAISON XL Anti-HDV using a well-characterized specimen panel, comprising HDV RNA positive (n = 62) and negative (n = 70) samples, and healthy US blood donors.</p></div><div><h3>Results</h3><p>Healthy US blood donors (n=200) showed 99.5% (199/200, 95%CI=97.65–99.98) specificity with ARCHITECT HDV Ig and 98.5 % (197/200, 95 %CI = 96.10–99.64) with LIAISON Anti-HDV. Among known HDV RNA positive samples, ARCHITECT HDV Ig detected 59/62 demonstrating 95.2 % sensitivity while LIAISON Anti-HDV sensitivity was 90.3 % (56/62). Among 101 HBV positive samples, 70 were reactive in the ARCHITECT test, 59 of which tested positive for HDV RNA for a positive predictive value (PPV) for the presence of HDV RNA was 84.3 %. For LIAISON Anti-HDV, 79 specimens were reactive and 56 contained HDV RNA: PPV for HDV RNA was 70.9 %. Among 70 HDV RNA negative samples, 39 were HBV positive. ARCHITECT HDV Ig negative predictive value (NPV) was 71.8 % and LIAISON Anti-HDV NPV was 41 % for the HBV positive group, respectively.</p></div><div><h3>Conclusion</h3><p>When compared to the LIASON Anti-HDV test, the ARCHITECT HDV Ig assay demonstrated enhanced sensitivity and specificity and better NPV and PPV values for HDV RNA status. The ARCHITECT HDV Ig assay represents a promising tool for universal screening of all HBsAg-positive persons.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"173 ","pages":"Article 105689"},"PeriodicalIF":8.8,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653224000519/pdfft?md5=106f59cdb8004e10ffbc5d378d171a49&pid=1-s2.0-S1386653224000519-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141034091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical and clinical evaluation of the cobas Epstein–Barr virus test at a tertiary care cancer hospital","authors":"Cindy Lee ,&nbsp;Younmin Lim ,&nbsp;Deborah Saintine ,&nbsp;N.Esther Babady","doi":"10.1016/j.jcv.2024.105680","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105680","url":null,"abstract":"<div><h3>Background</h3><p>Epstein–Barr Virus (EBV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically monitored using quantitative molecular assays. The Cobas EBV test (Roche Molecular, Pleasanton, CA) has recently been FDA-cleared for the monitoring of EBV viral loads in plasma samples of transplant patients. In this study, we compared the viral loads obtained by a laboratory-developed test (EBV LDT) using Altona Analyte specific reagents (ASR) to those obtained on the Cobas EBV test.</p></div><div><h3>Methods</h3><p>The analytical performance of the assay was established using the EBV verification panel from Exact Diagnostics and the EBV ATCC strain B95-8. The clinical evaluation was performed using 343 plasma samples initially tested on the EBV LDT.</p></div><div><h3>Results</h3><p>The analytical sensitivity (&lt;18.8 IU/mL), precision (SD &lt; 0.17 log) and linear range (35.0 IU/mL to 1E + 08 IU/mL) of the Cobas EBV assay established by the manufacturers were confirmed. The strength of the qualitative agreement was substantial between the cobas EBV and the EBV LDT (85.6 %; <em>κ</em> = 0.71) and almost perfect when discordant results were resolved (96.4 %; <em>κ</em> = 0.93). The quantitative agreement was moderate (82.9 %; <em>κ</em> = 0.53) with the viral load obtained on the Cobas EBV test being lower across the linear range of the two tests (mean log difference of 1.0). While the absolute values of the viral loads were markedly different, the overall trends observed in patients with multiple consecutive results were similar between the two tests.</p></div><div><h3>Conclusions</h3><p>The Cobas EBV test provides an accurate and valid, in vitro diagnostic (IVD) option for monitoring of EBV viral loads in transplant patients and should provide an opportunity for increased standardization and commutability of tests results across laboratories.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"173 ","pages":"Article 105680"},"PeriodicalIF":8.8,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and genetic characteristics of norovirus in Hangzhou, China, in the postepidemic era","authors":"Danlei Chen ,&nbsp;Qingyi Shao ,&nbsp;Xuanwen Ru ,&nbsp;Simiao Chen ,&nbsp;Dongqing Cheng ,&nbsp;Qing Ye","doi":"10.1016/j.jcv.2024.105679","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105679","url":null,"abstract":"<div><h3>Objective</h3><p>Norovirus (NoV) is an important human pathogen that can cause severe gastroenteritis in vulnerable populations. This study aimed to analyze the epidemiological and genetic characteristics of 2021–2023 NoV in Hangzhou, China.</p></div><div><h3>Methods</h3><p>This study enrolled patients aged 0–18 years who underwent NoV RNA detection in the hospital between January 2021 and October 2023 and analyzed the epidemiological characteristics of NoV. Polymerase chain reaction (PCR) was used to detect NoV RNA. Subtype classification and whole-genome sequencing were performed.</p></div><div><h3>Results</h3><p>There was a high prevalence of NoV infection in 2023, with NoV-positive samples accounting for 63.10 % of the total number of positive samples collected during the three-year period. The prevalence was abnormally high in summer, and the number of positive samples accounted for 48.20 % of the total positive samples for the whole year, which was much greater than the level in the same period in previous years (2023, 48.20% vs 2021, 13.66% vs 2022, 15.21 %). The GⅡ.4 subtype played a leading role, followed by increased mixed infection with GⅠ.5 and GⅡ.4. Whole-genome sequencing results suggested that GII.P16-GⅡ.4 had R297H and D372N key locus mutations. The evolutionary rate was 4.29 × 10⁻³ for the RdRp gene and 4.84 × 10⁻³ for the VP1 gene. The RdRp gene and VP1 gene of NoV GII.P16-GⅡ.4 have undergone rapid population evolution during the COVID-19 epidemic.</p></div><div><h3>Conclusion</h3><p>In the summer of 2023, an abnormally high incidence of NoV appeared in Hangzhou, China. The major epidemic strain GII.P16-GⅡ.4 showed a certain range of gene mutations and a fast evolutionary rate.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105679"},"PeriodicalIF":8.8,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients","authors":"Priya S. Verghese ,&nbsp;Michael D. Evans ,&nbsp;Amy Hanson ,&nbsp;Justina Hathi ,&nbsp;Srinath Chinnakotla ,&nbsp;Arthur Matas ,&nbsp;Henry H. Balfour Jr","doi":"10.1016/j.jcv.2024.105678","DOIUrl":"10.1016/j.jcv.2024.105678","url":null,"abstract":"<div><h3>Background</h3><p>Valganciclovir (valG), a cytomegalovirus (CMV) prophylactic agent, has dose-limiting side effects. The tolerability and effectiveness of valacyclovir (valA) as CMV prophylaxis is unknown.</p></div><div><h3>Methods</h3><p>We conducted a randomized, open-label, single-center trial of valA versus valG for all posttransplant CMV prophylaxis in adult and pediatric kidney recipients. Participants were randomly assigned to receive valA or valG. Primary endpoints were the incidence of CMV viremia and side-effect related drug reduction with secondary assessment of incidence of EBV viremia.</p></div><div><h3>Results</h3><p>Of the 137 sequential kidney transplant recipients enrolled, 26 % were positive and negative for CMV antibody in donor and recipient respectively. The incidence of CMV viremia (4 of 71 [6 %]; 8 of 67 [12 %] <em>P</em> = 0.23), time to viremia (<em>P</em> = 0.16) and area under CMV viral load time curve (<em>P</em> = 0.19) were not significantly different. ValG participants were significantly more likely to require side-effect related dose reduction (15/71 [21 %] versus 1/66 [2 %] <em>P</em> = 0.0003). Leukopenia was the most common reason for valG dose reduction and granulocyte-colony stimulating factor was utilized for leukopenia recovery more frequently (25 % in valG vs 5 % in valA: <em>P</em> = 0.0007). Incidence of EBV viremia was not significantly different.</p></div><div><h3>Conclusions</h3><p>ValA has significantly less dose-limiting side effects than valG. In our study population, a significant increase in CMV viremia was not observed, in adults and children after kidney transplant, compared to valG.</p></div><div><h3>Trial Registration Number</h3><p>NCT01329185</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105678"},"PeriodicalIF":8.8,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular epidemiology of a Parainfluenza Type 3 virus outbreak: Informing infection control measures on adult hematology wards","authors":"Laura Hughes ,&nbsp;Lilli Gard ,&nbsp;Monika Fliss ,&nbsp;Martijn Bakker ,&nbsp;Carin Hazenberg ,&nbsp;Xuewei Zhou ,&nbsp;Paulien Vierdag ,&nbsp;Karin von Eije ,&nbsp;Andreas Voss ,&nbsp;Mariëtte Lokate ,&nbsp;Marjolein Knoester","doi":"10.1016/j.jcv.2024.105677","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105677","url":null,"abstract":"<div><h3>Objectives</h3><p>Parainfluenza virus type 3 (PIV3) outbreaks among hematology patients are associated with high morbidity and mortality. Prompt implementation of infection prevention (IP) measures has proven to be the most efficacious approach for controlling PIV3 outbreaks within this patient population. The most suitable IP measures can vary depending on the mode of virus transmission, which remains unidentified in most outbreaks. We describe the molecular epidemiology of an outbreak of PIV3 among hematology patients and the development of a new method that allows for the differentiation of outbreak and community strains, from which a closed outbreak could be inferred.</p></div><div><h3>Methods</h3><p>Patients were screened for respiratory viruses using multiplex-PCR. PIV3 positive samples with a cycle threshold (Ct)-value of &lt;31 underwent a retrospective characterization via an in-house developed sequence analysis of the hemagglutinin-neuraminidase (HN) gene.</p></div><div><h3>Results</h3><p>Between July and September 2022, 31 hematology patients were identified with PIV3. Although infection control measures were implemented, the outbreak persisted for nine weeks. Sequencing the HN gene of 27 PIV3 strains from 27 patients revealed that all outbreak strains formed a distinct cluster separate from the control strains, suggestive of a nosocomial transmission route.</p></div><div><h3>Conclusions</h3><p>Sequencing the HN gene of PIV3 strains in an outbreak setting enables outbreak strains to be distinguished from community strains. Early molecular characterization of PIV3 strains during an outbreak can serve as a tool in determining potential transmission routes. This, in turn, enables rapid implementation of targeted infection prevention measures, with the goal of minimizing the outbreak's duration and reducing associated morbidity and mortality.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105677"},"PeriodicalIF":8.8,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653224000398/pdfft?md5=01b2aa0bf9838dcebc3c308215f19027&pid=1-s2.0-S1386653224000398-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140644247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; Cepheid Xpert® Xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARD™ M10 Flu/RSV/SARS-CoV-2","authors":"Christel Barker Jensen ,&nbsp;Uffe Vest Schneider ,&nbsp;Tina Vasehus Madsen ,&nbsp;Xiaohui Chen Nielsen ,&nbsp;Chih Man German Ma ,&nbsp;Jette Krogh Severinsen ,&nbsp;Anne Mette Hoegh ,&nbsp;Amanda Bolt Botnen ,&nbsp;Ramona Trebbien ,&nbsp;Jan Gorm Lisby","doi":"10.1016/j.jcv.2024.105674","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105674","url":null,"abstract":"<div><h3>Background</h3><p>Rapid and accurate detection of viral respiratory infections is important for infection control measures. This study compares the analytical and clinical performance of the Xpert® Xpress CoV-2/Flu/RSV <em>plus</em> test (“Xpert”, Cepheid) and the STANDARD™ M10 Flu/RSV/SARS-CoV-2 test (“M10”, SD Biosensor). Both tests are quadruplex RT-PCR assays for rapid diagnosis of SARS-CoV-2, influenza A/B and RSV.</p></div><div><h3>Study design</h3><p>Analytical sensitivities were determined by limit of detection for SARS-CoV-2, influenza A, influenza B and RSV, respectively. Additionally, the clinical performance of the Xpert and the M10 tests was evaluated against standard-of-care RT-PCR by testing of 492 clinical specimens.</p></div><div><h3>Results</h3><p>The analytical sensitivities for Xpert versus M10 test was 10, 50, 50 and 300 versus 300, 200, 800 and 1500 copies/mL for SARS-CoV-2, influenza A, influenza B and RSV, respectively. Clinical sensitivity for the Xpert test was superior across all four pathogens compared to the M10 test. Xpert showed clinical sensitivity of 100 % in all Ct-ranges for all four pathogens whereas M10 showed clinical sensitivity of 100 % in the 25–30 Ct-range, 84–100 % in the 30–35 Ct-range and 47–67 % in the &gt;35 Ct-range across the four pathogens. Translating into real-life clinical sensitivity, the Xpert would detect 100 % of all four pathogens, whereas M10 would detect 92.1, 92.4, 84.8 and 94.7 % for SARS-CoV-2, influenza A, influenza B and RSV.</p></div><div><h3>Conclusion</h3><p>This study demonstrates improved analytical and clinical performance of Xpert Xpress CoV-2/Flu/RSV <em>plus</em> compared to STANDARD M10 Flu/RSV/SARS-CoV-2, which is important for ensuring accuracy of diagnosis at all stages of a respiratory infection.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105674"},"PeriodicalIF":8.8,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653224000362/pdfft?md5=7458aa65c3c562d9f5fef2f7548a65a6&pid=1-s2.0-S1386653224000362-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140621835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the detection of viruses causing gastroenteritis over a 10-year period and impact of nonpharmaceutical interventions","authors":"Kibum Jeon ,&nbsp;Su Kyung Lee ,&nbsp;Seri Jeong ,&nbsp;Wonkeun Song ,&nbsp;Han-Sung Kim ,&nbsp;Jae-Seok Kim ,&nbsp;Kyu Sung Shin ,&nbsp;Hyun Soo Kim","doi":"10.1016/j.jcv.2024.105676","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105676","url":null,"abstract":"<div><h3>Background</h3><p>Viral gastroenteritis continues to be a leading cause of death in low-income countries. The impact of nonpharmaceutical interventions (NPIs) on the transmission of gastroenteritis-causing viruses during the COVID-19 pandemic is understudied.</p></div><div><h3>Objectives</h3><p>To investigate the 10-year trends of enteric viruses and estimate the impact of implementing and mitigating NPIs.</p></div><div><h3>Study design</h3><p>Data regarding norovirus, rotavirus, adenovirus, astrovirus, and sapovirus detection were collected from five Korean hospitals between January 2013 and April 2023. We compared positivity between the pre-pandemic, pandemic, and post-pandemic periods. The causal effects of implementing and mitigating NPIs were quantified using the Bayesian Structural Time Series (BSTS) model.</p></div><div><h3>Results</h3><p>Norovirus was most frequently detected (9.9 %), followed by rotavirus (6.7 %), adenovirus (3.3 %), astrovirus (1.4 %), and sapovirus (0.6 %). During the pandemic, the positivity of all five viruses decreased, ranging from -1.0 % to -8.1 %, with rotavirus showing the greatest decrease. In the post-pandemic period, positivity rebounded for all viruses except for rotavirus. The BSTS model revealed that NPI implementation negatively affected the detection of all five viruses, resulting in reductions ranging from -73.0 % to -91.0 % compared to the prediction, with rotavirus being the least affected. Conversely, NPI mitigation positively affected the detection of all viruses, ranging from 79.0 % to 200.0 %, except for rotavirus.</p></div><div><h3>Conclusions</h3><p>Trends observed over 10 years show that NPIs have had a major impact on changes in enteric virus detection. The effect of vaccines, in addition to NPIs, on rotavirus detection requires further investigation. Our findings emphasize the importance of NPIs in infection control and prevention.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105676"},"PeriodicalIF":8.8,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653224000386/pdfft?md5=8cdd6d4f37086e0433bb6bda72187ec8&pid=1-s2.0-S1386653224000386-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term follow-up of a series of 24 congenital CMV-infected babies with false negative amniocentesis","authors":"Caroline De Coninck ,&nbsp;Catherine Donner ,&nbsp;Elena Costa ,&nbsp;Serine Abbas ,&nbsp;Marie-Luce Delforge","doi":"10.1016/j.jcv.2024.105675","DOIUrl":"10.1016/j.jcv.2024.105675","url":null,"abstract":"<div><h3>Background</h3><p>Congenital CMV infection is the most common congenital infection worldwide and a major cause of neurological impairment and sensorineural hearing loss. Fetal CMV infection is confirmed by a positive PCR test in the amniotic fluid (amniocentesis performed after 18–20 weeks of gestation and at least 8 weeks after maternal infection). However, despite a negative antenatal CMV PCR result, some newborns can be tested positive at birth. Although not widely documented, the prognosis for these babies appears to be good.</p></div><div><h3>Objectives</h3><p>The aim of this study is to evaluate the long-term prognosis of fetuses with a false-negative AFS for cCMV, with a minimum follow-up period of 6 years.</p></div><div><h3>Study design</h3><p>This is a retrospective cohort study of false-negative amniocentesis reported at the CUB-Hôpital Erasme and Hôpital CHIREC in Brussels between 1985 and 2017.</p></div><div><h3>Results</h3><p>Of the 712 negative CMV PCR amniocenteses, 24 had a CMV PCR positive at birth. The false negative rate was 8.6 %. Of the 24 cases, 9 primary maternal infections occurred in the first trimester, 14 in the second trimester and 1 in the third trimester. Among the 24 children, 2 had symptoms at birth (hyperbilirubinemia and left paraventricular cysts), but all had normal follow-up (minimum 4 years, mean 16,6 years).</p></div><div><h3>Discussion</h3><p>Only 2 cases could be explained by early amniocentesis. Among the others, the false-negative results could be attributed to a low viral load, a delayed infection or, less likely, to a sample degradation.</p></div><div><h3>Conclusion</h3><p>Despite the false-negative results, all 24 children had a normal long-term follow-up.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105675"},"PeriodicalIF":8.8,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140612318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hybrid capture-based next-generation sequencing of new and old world Orthohantavirus strains and wild-type Puumala isolates from humans and bank voles","authors":"William Rosenbaum ,&nbsp;Erik Bovinder Ylitalo ,&nbsp;Guillaume Castel ,&nbsp;Andreas Sjödin ,&nbsp;Pär Larsson ,&nbsp;Julia Wigren Byström ,&nbsp;Mattias N.E. Forsell ,&nbsp;Clas Ahlm ,&nbsp;Lisa Pettersson ,&nbsp;Anne Tuiskunen Bäck","doi":"10.1016/j.jcv.2024.105672","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105672","url":null,"abstract":"<div><p>Orthohantaviruses, transmitted primarily by rodents, cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome in the Americas. These viruses, with documented human-to-human transmission, exhibit a wide case-fatality rate, 0.5–40 %, depending on the virus species, and no vaccine or effective treatment for severe Orthohantavirus infections exists. In Europe, the Puumala virus (PUUV), carried by the bank vole <em>Myodes glareolus</em>, causes a milder form of HFRS. Despite the reliance on serology and PCR for diagnosis, the three genomic segments of Swedish wild-type PUUV have yet to be completely sequenced.</p><p>We have developed a targeted hybrid-capture method aimed at comprehensive genomic sequencing of wild-type PUUV isolates and the identification of other Orthohantaviruses. Our custom-designed panel includes &gt;11,200 probes covering the entire <em>Orthohantavirus</em> genus. Using this panel, we sequenced complete viral genomes from bank vole lung tissue, human plasma samples, and cell-cultured reference strains. Analysis revealed that Swedish PUUV isolates belong to the Northern Scandinavian lineage, with nucleotide diversity ranging from 2.8 % to 3.7 % among them. Notably, no significant genotypic differences were observed between the viral sequences from reservoirs and human cases except in the nonstructural protein.</p><p>Despite the high endemicity of PUUV in Northern Sweden, these are the first complete Swedish wild-type PUUV genomes and substantially increase our understanding of PUUV evolution and epidemiology. The panel's sensitivity enables genomic sequencing of human samples with viral RNA levels reflecting the natural progression of infection and underscores our panel's diagnostic value, and could help to uncover novel Orthohantavirus transmission routes.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"172 ","pages":"Article 105672"},"PeriodicalIF":8.8,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1386653224000349/pdfft?md5=b30380705f0d32f1fee7d03b15475f29&pid=1-s2.0-S1386653224000349-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140341410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}